115 related articles for article (PubMed ID: 16863913)
1. Synergistic inhibition in vivo of bone marrow myeloid progenitors by myelosuppressive chemokines and chemokine-accelerated recovery of progenitors after treatment of mice with Ara-C.
Broxmeyer HE; Pelus LM; Kim CH; Hangoc G; Cooper S; Hromas R
Exp Hematol; 2006 Aug; 34(8):1069-77. PubMed ID: 16863913
[TBL] [Abstract][Full Text] [Related]
2. Class II transactivator-mediated regulation of major histocompatibility complex class II antigen expression is important for hematopoietic progenitor cell suppression by chemokines and iron-binding proteins.
Broxmeyer HE; Cooper S; Hangoc G; Chang CH
Exp Hematol; 2006 Aug; 34(8):1078-84. PubMed ID: 16863914
[TBL] [Abstract][Full Text] [Related]
3. Stromal cell-derived factor-1/CXCL12 selectively counteracts inhibitory effects of myelosuppressive chemokines on hematopoietic progenitor cell proliferation in vitro.
Broxmeyer HE; Cooper S; Hangoc G; Kim CH
Stem Cells Dev; 2005 Apr; 14(2):199-203. PubMed ID: 15910246
[TBL] [Abstract][Full Text] [Related]
4. The chemokine CCL21 protects normal marrow progenitors from Ara-C cytotoxicity.
Hromas R; Cooper S; Broxmeyer HE
Cancer Chemother Pharmacol; 2002 Aug; 50(2):163-6. PubMed ID: 12172984
[TBL] [Abstract][Full Text] [Related]
5. Myelosuppressive effects in vivo with very low dosages of monomeric recombinant murine macrophage inflammatory protein-1 alpha.
Cooper S; Mantel C; Broxmeyer HE
Exp Hematol; 1994 Feb; 22(2):186-93. PubMed ID: 8299739
[TBL] [Abstract][Full Text] [Related]
6. Myeloid progenitor cell proliferation and mobilization effects of BB10010, a genetically engineered variant of human macrophage inflammatory protein-1alpha, in a phase I clinical trial in patients with relapsed/refractory breast cancer.
Broxmeyer HE; Orazi A; Hague NL; Sledge GW; Rasmussen H; Gordon MS
Blood Cells Mol Dis; 1998 Mar; 24(1):14-30. PubMed ID: 9516378
[TBL] [Abstract][Full Text] [Related]
7. A novel anti-inflammatory function of human galectin-1: inhibition of hematopoietic progenitor cell mobilization.
Kiss J; Kunstár A; Fajka-Boja R; Dudics V; Tóvári J; Légrádi A; Monostori E; Uher F
Exp Hematol; 2007 Feb; 35(2):305-13. PubMed ID: 17258079
[TBL] [Abstract][Full Text] [Related]
8. Myelosuppressive effects in vivo of purified recombinant murine macrophage inflammatory protein-1 alpha.
Maze R; Sherry B; Kwon BS; Cerami A; Broxmeyer HE
J Immunol; 1992 Aug; 149(3):1004-9. PubMed ID: 1634758
[TBL] [Abstract][Full Text] [Related]
9. Human chemokines: enhancement of specific activity and effects in vitro on normal and leukemic progenitors and a factor-dependent cell line and in vivo in mice.
Broxmeyer HE; Cooper S; Hague N; Benninger L; Sarris A; Cornetta K; Vadhan-Raj S; Hendrie P; Mantel C
Ann Hematol; 1995 Nov; 71(5):235-46. PubMed ID: 7492626
[TBL] [Abstract][Full Text] [Related]
10. Accelerated recovery of 5-fluorouracil-damaged bone marrow after rosiglitazone treatment.
Djazayeri K; Szilvássy Z; Peitl B; Németh J; Nagy L; Kiss A; Szabó B; Benko I
Eur J Pharmacol; 2005 Oct; 522(1-3):122-9. PubMed ID: 16213483
[TBL] [Abstract][Full Text] [Related]
11. The enhanced cytotoxicity of combinations of 1-beta-D-arabinofuranosylcytosine and methotrexate.
Edelstein M; Vietti T; Valeriote F
Cancer Res; 1975 Jun; 35(6):1555-8. PubMed ID: 1131822
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic effects of 1-beta-D-arabinofuranosylcytosine and 6-thioguanine in vitro on granulocytic progenitor cells.
Greenberg PL; VanKersen I; Mosny S
Cancer Res; 1976 Dec; 36(12):4412-7. PubMed ID: 1069606
[TBL] [Abstract][Full Text] [Related]
13. In vivo myelosuppression by combination interferon treatment: antagonism of MuIFN-gamma and MuIFN-beta myelosuppressive effects.
Naldini A; Fleischmann WR
J Biol Response Mod; 1987 Oct; 6(5):546-55. PubMed ID: 3119781
[TBL] [Abstract][Full Text] [Related]
14. In vivo activity of the cleaved form of soluble urokinase receptor: a new hematopoietic stem/progenitor cell mobilizer.
Selleri C; Montuori N; Ricci P; Visconte V; Baiano A; Carriero MV; Rotoli B; Rossi G; Ragno P
Cancer Res; 2006 Nov; 66(22):10885-90. PubMed ID: 17108125
[TBL] [Abstract][Full Text] [Related]
15. Effect of leukotactin-1 on the protection in vivo of myeloid progenitor cells against cytotoxic chemotherapeutics.
Kim WY; Broxmeyer HE; Han IS; Park DH; Lee KM; Vinay DS; Kwon BS
J Hematother Stem Cell Res; 2003 Feb; 12(1):107-13. PubMed ID: 12662441
[TBL] [Abstract][Full Text] [Related]
16. [Mice transduced with double-mutant dihydrofolate reductase-cytidine deaminase fusion gene attained protection from high dose chemotherapy].
Lu P; Lu Y; Pang K; Wang SB; Chen JQ; Xu HM; Wang JK; Zhao SC
Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):998-1001. PubMed ID: 16194358
[TBL] [Abstract][Full Text] [Related]
17. Cyclin dependent kinase inhibitors differentially modulate synergistic cytokine responsiveness of hematopoietic progenitor cells.
Broxmeyer HE; Franklin DS; Cooper S; Hangoc G; Mantel C
Stem Cells Dev; 2012 Jul; 21(10):1597-603. PubMed ID: 21936707
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic precursor cell exhaustion is a cause of proliferative defect in primitive hematopoietic stem cells (PHSC) after chemotherapy.
Gardner RV; Astle CM; Harrison DE
Exp Hematol; 1997 Jun; 25(6):495-501. PubMed ID: 9197327
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo expanded hematopoietic progenitor cells improve cardiac function after myocardial infarction: role of beta-catenin transduction and cell dose.
Templin C; Kotlarz D; Faulhaber J; Schnabel S; Grote K; Salguero G; Luchtefeld M; Hiller KH; Jakob P; Naim HY; Schieffer B; Hilfiker-Kleiner D; Landmesser U; Limbourg FP; Drexler H
J Mol Cell Cardiol; 2008 Sep; 45(3):394-403. PubMed ID: 18671980
[TBL] [Abstract][Full Text] [Related]
20. Human periosteum-derived progenitor cells express distinct chemokine receptors and migrate upon stimulation with CCL2, CCL25, CXCL8, CXCL12, and CXCL13.
Stich S; Loch A; Leinhase I; Neumann K; Kaps C; Sittinger M; Ringe J
Eur J Cell Biol; 2008 Jun; 87(6):365-76. PubMed ID: 18501472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
